Genetic alterations and signaling pathways in the evolution of gliomas

@article{Ohgaki2009GeneticAA,
  title={Genetic alterations and signaling pathways in the evolution of gliomas},
  author={Hiroko Ohgaki and Paul Kleihues},
  journal={Cancer Science},
  year={2009},
  volume={100}
}
Gliomas are the most common primary brain tumors. They account for more than 70% of all neoplasms of the central nervous system and vary considerably in morphology, location, genetic alterations, and response to therapy. Most frequent and malignant are glioblastomas. The vast majority (>90%) develops rapidly after a short clinical history and without evidence of a less malignant precursor lesion (primary or de novo glioblastoma). Secondary glioblastomas develop more slowly through progression… 
Developmental origins and oncogenic pathways in malignant brain tumors
TLDR
Current understanding of tumor cells of origin, heterogeneity, recurring genetic and epigenetic alterations, oncogenic drivers and signaling pathways for adult glioblastomas, pediatric high‐grade gliomas, and medulloblastoma, the genetically heterogeneous groups of malignant brain tumors are discussed.
Molecular diagnostics of gliomas.
TLDR
An overview of the most common molecular markers in neurooncology, including 1p/19q codeletion in oligodendroglial tumors, mutations in the isocitrate dehydrogenase 1 and 2 genes in diffuse gliomas, and hypermethylation of the O(6)-methylguanine-DNA methyltransferase gene promoter in glioblastomas and anaplasticgliomas are provided.
Gliomas: Role of Wnt/β-Catenin/Tcf Signaling Pathway
TLDR
Astrocytomas are divided into four clinical grades on the basis of analysis of the most malignant tumor region, number of mitoses, nuclear atypia, microvascular proliferation and presence of necrosis, and glioblastoma multiforme (GBM) is mostmalignant, aggressive and devastating form with a worse prognosis.
New Insights Into Molecular Basis of Glioblastoma Multiforme and Associated Immunosuppression
TLDR
This review summarizes the current knowledge regarding genetic alterations and signaling pathways critical to the biology of GBMs, few mechanisms of developing local and systemic GBM-induced immunosuppression, and the role of GBM stem cells.
13 Genetics and Biology of Glioblastoma Multiforme
TLDR
It is still not possible to distinguish, in advance, which patients are the most likely to effectively benefit from specific drugs, but recent data have reported that hypermethylation of the O6methylguanine-DNA methyltransferase gene promoter is associated with prolonged progression-free survival in GBM patients treated with alkylating agents.
Intratumor heterogeneity, microenvironment, and mechanisms of drug resistance in glioma recurrence and evolution
TLDR
The different mechanisms involved in glioma progression, including tumor heterogeneity, the tumor microenvironment and drug resistance, and their pre-clinical implements in clinical trials are introduced.
Pediatric low-grade glioma in the era of molecular diagnostics
TLDR
How molecular information can help to further define the entities which fall under the umbrella of pediatric-type low-grade glioma is reviewed and a risk-based stratification system that considers both clinical and molecular parameters to aid clinicians in making treatment decisions is proposed.
Cerebral Glioblastoma: A Review on Genetic Alterations, Signaling Pathways, and Clinical Management
TLDR
The genetic alterations and cellular pathways which could lead to the appearance of this tumor were highlighted, and the latest options for treating patients dealing with glioblastoma were discussed.
Implications of mitogen‐activated protein kinase signaling in glioma
TLDR
The present review focuses on recent literature regarding important deregulations in the RTK‐activated MAPK pathway during gliomagenesis and progression.
...
...

References

SHOWING 1-10 OF 112 REFERENCES
Genetic pathways to primary and secondary glioblastoma.
TLDR
Primary and secondary glioblastomas constitute distinct disease subtypes, affecting patients of different age and developing through different genetic pathways, and differ significantly in their pattern of promoter methylation and in expression profiles at RNA and protein levels.
Distinct transcription profiles of primary and secondary glioblastoma subgroups.
TLDR
Large-scale expression analyses were used to identify glioblastoma-associated genes (GAG) that are associated with a more malignant phenotype via comparison with lower-grade astrocytomas and highlight that the development of gene pathway-targeted therapies may need to be specifically tailored to each subtype of gliOBlastoma.
Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas
TLDR
Data indicate that overexpression of the EGF receptor and mutations of the p53 tumor suppressor gene are mutually exclusive events defining two different genetic pathways in the evolution of glioblastoma as the common phenotypic endpoint.
Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas.
TLDR
Data indicate that overexpression of the EGF receptor and mutations of the p53 tumor suppressor gene are mutually exclusive events defining two different genetic pathways in the evolution of glioblastoma as the common phenotypic endpoint.
Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
TLDR
P16 deletions were significantly more frequent in the former (10/28; 36%) than in the latter (1/23, 4%; P = 0.0075), suggesting that this alteration constitutes an additional genetic hallmark of the primary (de novo) glioblastoma.
Amplification and Overexpression of MDM2 in Primary (de novo) Glioblastomas
TLDR
Results suggest that MDM2 overexpression with or without gene amplification constitutes a molecular mechanism of escape from p53-regulated growth control, operative in the evolution of primary glioblastomas that typically lack p53 mutations.
Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
TLDR
Allelic loss (or loss of heterozygosity) of chromosome 1p is a statistically significant predictor of chemosensitivity, and combined loss involving chromosomes 1p and 19q is statistically significantly associated with both chemos sensitivity and longer recurrence-free survival after chemotherapy.
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.
TLDR
It is demonstrated that human gliomas can be differentiated according to their gene expression, and found that low-grade astrocytoma have the most specific and similar expression profiles, whereas primary glioblastoma exhibit much larger variation between tumors.
Correlation Among Pathology, Genotype, and Patient Outcomes in Glioblastoma
TLDR
The results suggest that some histologic features in glioblastomas are associated with specific genetic alterations and with clinical outcome, and the presence of an oligodendroglial component to be predictive of longer survival.
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
TLDR
Recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival.
...
...